PTH (7-34) Human

Parathyroid Hormone (7-34) is a fragment of the full-length PTH, which consists of 84 amino acids. The fragment (7-34) retains the biological activity necessary for binding to the PTH receptor but lacks the full spectrum of activity seen with the complete hormone . This truncated version is often used in research to study the specific interactions and functions of the hormone without the full physiological effects of the complete molecule.

The recombinant form of Parathyroid Hormone (7-34) is produced using genetic engineering techniques. The gene encoding the desired fragment is inserted into a suitable expression system, such as E. coli, which then produces the hormone fragment in large quantities . This method ensures a high degree of purity and consistency in the produced hormone, making it suitable for both research and therapeutic applications.

Recombinant human PTH, including its fragments like (7-34), is used in various medical applications. It is particularly significant in the treatment of conditions such as hypoparathyroidism, where the body produces insufficient amounts of PTH . By supplementing with recombinant PTH, it is possible to manage calcium levels more effectively in affected individuals.

The (7-34) fragment of PTH is extensively used in research to understand the hormone’s mechanism of action. Studies often focus on its role in bone metabolism, calcium regulation, and its potential therapeutic uses . The ability to produce this fragment recombinantly has opened up numerous avenues for scientific exploration and potential new treatments for related disorders.